RANI RANI
Company Profile ↓Company Overview
RANI (RANI) is a publicly traded company listed on with a market capitalization of $76.15M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 37.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.13.
Recent Developments
- Dec 2025 Revenue of $1.63M (+58.9% YoY); net profit $-29.67M.
- Trailing 12 Months Year-on-year growth — revenue +58.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 37.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 37.12% |
| 1 Year: | 58.85% |
Stock Price Performance
| 1 Year: | +42.34% |
| 6 Months: | -36.59% |
| 3 Months: | -11.76% |
| 1 Month: | +10.01% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 37.1% over 5 years.
CONS
- Trading 72.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 60.00K | 108.00K | 756.00K | 1.96M | 0 | - | 0 | 0 | - | - | - | 0 | 0 | 0 | 172.00K | 0 | 0 | 1.46M | 1.71M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.19M | 10.51M | 7.26M | 10.00M | 10.05M |
| Operating Income | - | -3.39M | -2.83M | -5.20M | -5.26M | -27.78M | -13.78M | -15.85M | -16.34M | -16.52M | -18.29M | -17.86M | -14.03M | -12.52M | -11.80M | -12.01M | -10.51M | -7.26M | -8.54M | -8.34M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.54M | -10.11M | -6.97M | -8.54M | -7.77M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 943.00K | 877.00K | 725.00K | 347.00K | 88.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.74M | -11.22M | -7.91M | -9.07M | -8.02M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.35M | -2.71M | -2.88M | -5.60M | -5.49M | -3.14M | -6.22M | -7.62M | -7.96M | -8.37M | -9.30M | -9.20M | -7.48M | -6.80M | -6.78M | -7.26M | -6.69M | -5.41M | -10.30M | -7.03M |
| Diluted EPS | - | - | - | - | - | -0.16 | 0.29 | 0.31 | 0.33 | -0.33 | -0.37 | -0.36 | -0.29 | -0.26 | -0.24 | -0.22 | -0.18 | -0.12 | -0.07 | -0.04 |
| R&D Expense | - | 2.56M | 2.09M | 3.35M | 3.76M | 11.96M | 7.59M | 9.53M | 9.10M | 9.71M | 11.09M | 11.22M | 7.59M | 6.12M | 6.17M | 6.57M | 5.50M | 3.22M | - | 5.16M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 462.00K | - | 0 | 0 | 1.03M | 1.63M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 63.45M | 66.10M | 50.63M | 39.94M |
| Operating Income | -16.54M | - | -63.45M | -66.10M | -49.60M | -38.31M |
| EBITDA | - | - | -61.66M | -61.98M | -50.52M | -37.16M |
| Interest Expense | - | - | 1.07M | 5.08M | 5.03M | 2.89M |
| Pretax Income | - | - | -63.27M | -67.88M | -56.58M | -40.95M |
| Tax Provision | - | 41.00K | 70.00K | 0 | - | - |
| Net Income | - | - | -30.59M | -33.97M | -30.02M | -29.67M |
| Diluted EPS | - | - | -1.28 | -1.33 | -1.05 | -0.45 |
| R&D Expense | 12.04M | 26.48M | 36.61M | 39.62M | 26.68M | 20.20M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | 79.42M | - | 108.03M | 57.92M | 36.63M | 58.62M |
| Current Assets | - | - | 100.92M | 50.85M | 29.74M | 53.32M |
| Cash & Equivalents | 73.06M | - | 27.01M | 5.86M | 3.76M | 18.62M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | - | - | 0 | 2.04M |
| Total Liabilities | 8.04M | - | 34.02M | 32.47M | 33.14M | 17.11M |
| Current Liabilities | 5.31M | - | 4.82M | 7.99M | 19.89M | 12.67M |
| Long Term Debt | 2.41M | - | 29.15M | 24.48M | 9.61M | - |
| Total Debt | - | - | 30.21M | 30.10M | 29.71M | 4.32M |
| Total Equity | -113.34M | - | 36.85M | 12.87M | 1.99M | 33.01M |
| Shares Outstanding | - | - | 25.30M | 26.04M | 33.43M | 97.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.96M | - | -46.52M | -51.24M | -35.50M | -18.71M |
| Investing Cash Flow | -1.20M | - | -72.44M | 29.86M | 19.81M | -7.03M |
| Financing Cash Flow | 72.68M | - | 29.00M | 233.00K | 13.59M | 40.30M |
| Capital Expenditure | -1.20M | - | -1.62M | -1.23M | -268.00K | -88.00K |
| Free Cash Flow | -16.16M | - | -48.13M | -52.47M | -35.76M | -18.80M |
| Net Change in Cash | - | - | -89.95M | -21.14M | -2.10M | 14.56M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -3,581.0% | - | - | - | -4,824.9% | -2,346.0% |
| Net Margin % | - | - | - | - | -2,920.0% | -1,817.1% |
| ROE % | - | - | -83.0% | -264.0% | -1,506.9% | -89.9% |
| ROCE % | -22.3% | - | -61.5% | -132.4% | -296.2% | -83.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RANI
Rani Therapeutics Holdings, Inc. (RANI) details director option holding - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPVC1UNTBOdU54a3Ywdnh6RGxGYkkxU2p1TWFKTWE1RWVha2s3ZndueW1qLXlTdGRjSFQ4ZFRUS3JOMzdlRXhPdl9DOVpzU2QyX3JYMWR5VTJxR2hVTDhCa1ZLeG1FYlFKaGV0ZllQTFBJenpxQko4MEhmUEZyOVNlV0VSWl9yNnY4dk4yb0…
Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNa2JSdDU4SDdmcEd5V05zZVlMMTNEZV9NanY4bFFYcHZOTjQ1VzNtclQ5MzFLdkF3c2FJd0pKbjI2MDd6MThseFRDMmotci1NT3BCd0w0OVY2NDN5dFRIWUJBMlBmWjFYYS04VFgtWXZWd1R1dVU5WnhINFZKZjVKTFVxMmZSakUxdkE5aV…
This Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last Year - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPelQwaVhqMlFSZlhvMHpzcDAyc29qSEo1RVRGX2tYRVhaUS1WM21nS3NBTkQ4eXVWYndZS1R2NEFaN3dsWC1MX0FmWlZXODJrTXBpQ0hNTTE5SDhDa0lfblhrTmV3ZEd2djBIb2dCbnRaMHZ4UTg2ck01VzBxVnU1VGRjMjRCMHZDUXdzV2…
Rani Therapeutics Holdings, Inc. (RANI) awards 247,200 stock options to director - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOa2lvNUhlTjZjaUR2UjNRNmdQcHEwMC11SG4tTGY3dWE5eDJTZlg0MDllWTN0VFdWN2hiM1d0dlk2ekdjUWhIVUFxd3l6QjVsRzVudzZIOHFzMjBveEYwT3otSkFuaGtDQjQxZS0wV1lkdFA2SE9oekJqT1pOMlJ3Q1ZPZm5qZDlBVG85Yj…
Enterprise value to revenue forward of Rani Therapeutics Holdings, Inc. – NASDAQ:RANI - TradingView
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPVGFfZExET3ZfZVFmTEI5WkNpUGdTRUhMdFpKeXQwUFBSaWNpeE9XRWItX1doVnYxdmpLUTFkVnhjUjNRYXZEalA1bjhpaTVvemkyUE5xQlpmSnRHSFV2Q0h0bDBhRXdEX0EydndPZ2V6bTVPS3oxclZJaTV6ZWMwMG9mVS04Nkc1TUExen…
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxPeFdyMmFkVW1TRU5fclNMd29scW9GT2d2TmlzR1ZVVTc1OG9ldE1yUVRtYi1iNjhFX1dqS2pKRHNCOElpSTRDYzFKdWlzX0JrU01OczYwTjBReXVaS0x0YUpZVnR5a0twZV9MR01oTFJqelpmQS1PZXhJZWREanR5M2ZOdTlMaWZUZS0xLT…
RANI — Frequently Asked Questions
What is the current share price of RANI?
As of 2026-08-05 17:25 PDT, RANI trades at $0.78 on NASDAQ/NYSE. Its 52-week range is $0.46 to $2.85.
What is the market capitalisation of RANI?
RANI has a market capitalisation of $76.15M on NASDAQ/NYSE.
What is the P/E ratio of RANI?
RANI trades at a trailing price-to-earnings (P/E) ratio of -1.73. Its price-to-book (P/B) ratio is 2.31.
What is the return on equity (ROE) of RANI?
RANI has a return on equity (ROE) of -89.89%. Its return on capital employed (ROCE) is -83.37%.
Is RANI a good stock to buy?
This page provides a data-driven analysis of RANI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.